应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
STSA Satsuma Pharmaceuticals, Inc.
退市 06-07 16:00:00 EDT
1.10
+0.00
0.00%
最高
1.10
最低
1.10
成交量
0.00
今开
1.10
昨收
1.10
日振幅
0.00%
总市值
3,647万
流通市值
1,672万
总股本
3,315万
成交额
194.10万
换手率
0.00%
流通股本
1,520万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告
智通财经 · 06-18
舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告
舒泰神(300204.SZ)获STSA-1002注射液和STSA-1005注射液临床研究总结报告
智通财经 · 02-06
舒泰神(300204.SZ)获STSA-1002注射液和STSA-1005注射液临床研究总结报告
舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批
智通财经网 · 01-03
舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批
加载更多
公司概况
公司名称:
Satsuma Pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发一种治疗偏头痛急性治疗的新型治疗药物。
发行价格:
--
{"stockData":{"symbol":"STSA","market":"US","secType":"STK","nameCN":"Satsuma Pharmaceuticals, Inc.","latestPrice":1.1,"timestamp":1686168000000,"preClose":1.1,"halted":4,"volume":0,"delay":0,"floatShares":15203712,"shares":33152498,"eps":-1.999338,"marketStatus":"退市","marketStatusCode":5,"change":0,"latestTime":"06-07 16:00:00 EDT","open":1.1,"high":1.1,"low":1.1,"amount":1940959.886414,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.999338,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721203200000},"adr":0,"listingDate":1568347200000,"adjPreClose":1.1,"volumeRatio":0},"requestUrl":"/m/hq/s/STSA","defaultTab":"news","newsList":[{"id":"2444108417","title":"舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2444108417","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444108417?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:08","pubTimestamp":1718698111,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神(300204.SZ)公告,近日,公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。I期临床试验结果显示,在方案设计的剂量范围内,STSA-1201皮下注射液在健康受试者中单次给药的安全性和耐受性良好,未检出抗药抗体,且药物代谢呈线性药代动力学特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["STSA","300204","BK4007","BK0028","BK0239","BK0046"],"gpt_icon":0},{"id":"2409342608","title":"舒泰神(300204.SZ)获STSA-1002注射液和STSA-1005注射液临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2409342608","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409342608?lang=zh_cn&edition=full","pubTime":"2024-02-06 17:24","pubTimestamp":1707211492,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神(300204.SZ)发布公告,公司近日取得关于STSA-1002注射液和STSA-1005注射液联用的I期临床研究总结报告,主要研究结论如下:1、STSA-1005注射液在临床试验剂量组剂量范围内及STSA-1002注射液在临床试验剂量组剂量范围内联合静脉给药,显示出良好的安全和耐受性。2、STSA-1002注射液和STSA-1005注射液同时给药均不会影响各自在健康受试者中的暴露。3、STSA-1005注射液和STSA-1002注射液在中国健康受试者中免疫原性较弱;给药后能明显抑制体内C5a水平,抑制时间随剂量的增加而延长;不增加健康人炎性细胞因子的表达。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1069383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","STSA"],"gpt_icon":0},{"id":"2400490844","title":"舒泰神(300204.SZ):单抗药物STSA-1001注射液开展癌痛的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2400490844","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2400490844?lang=zh_cn&edition=full","pubTime":"2024-01-03 16:08","pubTimestamp":1704269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯,舒泰神 发布公告,近日,公司收到了国家药品监督管理局签发的STSA-1001注射液用于治疗癌痛的《药物临床试验批准通知书》,同意本品开展癌痛的临床试验。据悉,STSA-1001注射液是一种重组抗NGF的全人源IgG1单克隆抗体注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1049489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1141","BK4007","03347","BK1583","BK1576","STSA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.satsumarx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0345},{"period":"3month","weight":0.1152},{"period":"6month","weight":0.189},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.1814}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立,是一家临床阶段的生物制药公司,开发一种治疗偏头痛急性治疗的新型治疗药物。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.18106},{"month":2,"riseRate":0.5,"avgChangeRate":-0.018348},{"month":3,"riseRate":0.25,"avgChangeRate":-0.137},{"month":4,"riseRate":0.5,"avgChangeRate":0.08762},{"month":5,"riseRate":0.25,"avgChangeRate":0.034529},{"month":6,"riseRate":1,"avgChangeRate":0.195405},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.113868},{"month":8,"riseRate":0.333333,"avgChangeRate":0.112636},{"month":9,"riseRate":0,"avgChangeRate":-0.31806},{"month":10,"riseRate":0.25,"avgChangeRate":-0.048014},{"month":11,"riseRate":0.5,"avgChangeRate":-0.101074},{"month":12,"riseRate":0.5,"avgChangeRate":0.052715}],"exchange":"NASDAQ","name":"Satsuma Pharmaceuticals, Inc.","nameEN":"Satsuma Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.0","shortVersion":"4.25.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Satsuma Pharmaceuticals, Inc.,STSA,Satsuma Pharmaceuticals, Inc.股票,Satsuma Pharmaceuticals, Inc.股票老虎,Satsuma Pharmaceuticals, Inc.股票老虎国际,Satsuma Pharmaceuticals, Inc.行情,Satsuma Pharmaceuticals, Inc.股票行情,Satsuma Pharmaceuticals, Inc.股价,Satsuma Pharmaceuticals, Inc.股市,Satsuma Pharmaceuticals, Inc.股票价格,Satsuma Pharmaceuticals, Inc.股票交易,Satsuma Pharmaceuticals, Inc.股票购买,Satsuma Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}